Veracyte Announces In Vitro Diagnostic Agreement With Illumina To Broaden Availability Of Its Tests For Patients Globally
Portfolio Pulse from Benzinga Newsdesk
Veracyte, Inc. (NASDAQ:VCYT) has entered into a multi-year agreement with Illumina, Inc. (NASDAQ:ILMN) to develop and offer some of its molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina's NextSeq 550Dx instrument. The first tests that Veracyte plans to develop are its Prosigna Breast Cancer Assay and Percepta Nasal Swab test. Veracyte is also developing its Decipher Prostate Genomic Classifier as a qPCR-based test for use outside of the U.S.
November 07, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina's partnership with Veracyte to offer Veracyte's molecular tests on its NextSeq 550Dx instrument could potentially increase its usage and revenues.
The partnership with Veracyte allows Illumina to increase the usage of its NextSeq 550Dx instrument, potentially increasing its market reach and revenues.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Veracyte's partnership with Illumina to develop and offer its molecular tests on Illumina's NextSeq 550Dx instrument could potentially increase its global reach and revenues.
The partnership with Illumina allows Veracyte to develop and offer its molecular tests on a globally recognized platform, potentially increasing its market reach and revenues.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100